Within the tumor lysate CTX upregulated MIG but also increased RANTES (CCL5) a known macrophage recruiting cytokine (39), and this could potentially explain why tumors recur post CTX treatment cessation (Figure S2F and Supplementary table S13). Here, CXCL9 is linked to neoplasm.